Cognios Capital LLC Takes Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Cognios Capital LLC acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 5,138 shares of the medical research company’s stock, valued at approximately $1,496,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. State of Michigan Retirement System boosted its holdings in Thermo Fisher Scientific by 4.1% during the third quarter. State of Michigan Retirement System now owns 329,931 shares of the medical research company’s stock worth $96,099,000 after purchasing an additional 13,100 shares during the last quarter. Private Vista LLC boosted its holdings in Thermo Fisher Scientific by 4.6% during the third quarter. Private Vista LLC now owns 1,493 shares of the medical research company’s stock worth $435,000 after purchasing an additional 65 shares during the last quarter. World Asset Management Inc boosted its holdings in Thermo Fisher Scientific by 0.5% during the third quarter. World Asset Management Inc now owns 24,921 shares of the medical research company’s stock worth $7,259,000 after purchasing an additional 118 shares during the last quarter. Cibc Bank USA boosted its holdings in Thermo Fisher Scientific by 5.9% during the third quarter. Cibc Bank USA now owns 3,337 shares of the medical research company’s stock worth $972,000 after purchasing an additional 186 shares during the last quarter. Finally, Virginia Retirement Systems ET AL boosted its holdings in Thermo Fisher Scientific by 532.5% during the third quarter. Virginia Retirement Systems ET AL now owns 99,300 shares of the medical research company’s stock worth $28,923,000 after purchasing an additional 83,600 shares during the last quarter. Hedge funds and other institutional investors own 88.21% of the company’s stock.

TMO opened at $296.93 on Thursday. The company has a quick ratio of 1.07, a current ratio of 1.49 and a debt-to-equity ratio of 0.58. The stock has a market cap of $112.53 billion, a price-to-earnings ratio of 26.70, a PEG ratio of 1.84 and a beta of 1.13. Thermo Fisher Scientific Inc. has a twelve month low of $208.34 and a twelve month high of $305.45. The company’s 50-day moving average price is $288.56 and its two-hundred day moving average price is $281.56.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 23rd. The medical research company reported $2.94 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.88 by $0.06. The firm had revenue of $6.27 billion for the quarter, compared to analysts’ expectations of $6.19 billion. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.11%. The company’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the company earned $2.62 earnings per share. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 12.25 earnings per share for the current year.

TMO has been the topic of several analyst reports. Needham & Company LLC boosted their price target on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Credit Suisse Group restated a “buy” rating and set a $310.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, July 31st. Barclays set a $330.00 price target on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Monday, July 15th. ValuEngine cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. restated an “overweight” rating and set a $330.00 price target (up from $315.00) on shares of Thermo Fisher Scientific in a report on Wednesday. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $307.33.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 2,271 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $298.00, for a total value of $676,758.00. Following the transaction, the chief executive officer now directly owns 283,502 shares in the company, valued at $84,483,596. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Jim P. Manzi sold 1,833 shares of the business’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $272.93, for a total transaction of $500,280.69. Following the completion of the transaction, the director now owns 28,592 shares in the company, valued at $7,803,614.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 54,104 shares of company stock worth $15,418,539. Corporate insiders own 0.45% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Recommended Story: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.